Abu Dhabi (ots) - Kevin Hofer zeigte an den WorldSkills 2017 gute Leistungen: Der 22-Jährige Rothrister ...
Olivier Bohuon Joins Pierre Fabre
Castres, France, July 2, 2010 (ots/PRNewswire) - Olivier Bohuon will be replacing Jean-Pierre Garnier as Chief Executive Officer at Pierre Fabre Group starting September 1, 2010.
Until now, Olivier Bohuon, 51, was Executive Vice-President of the Abbott Corporation and President of its pharmaceutical division. As such, he ran the group's entire pharmaceutical activities from Chicago ($22 billion in sales). In 2003, he was named the group's President for European operations and later became President of Abbott International.
Prior to that, before beginning his career at Roussel Uclaf in Morocco (and later in the Middle East), Olivier Bohuon was the Marketing Director and then the Operations Director of Glaxo France (1991-1995), CEO and then President of SmithKline Beecham Laboratories (1995-2001), and Director of GlaxoSmithKline's Commercial Operations, Europe (2001-2003).
Olivier Bohuon holds a Doctor of Pharmacy as well as an HEC MBA.
He is a member of the National Pharmacy Academy and the Academy of Technologies and is a knight of the Légion d'Honneur.
After an international career, at the end of which he was entrusted with the highest operational responsibilities within the pharmaceutical sector, Olivier Bohuon chose to return to France to pursue his career there.
In addition to his duties as the group's CEO, he will also act as President of Pierre Fabre Medicament.
When his arrival at Pierre Fabre was announced, Olivier BOHUON stated, "I will head the group in close collaboration with his chairman and founder and we will jointly paving the future; my action will be registered in the long run."
About the Pierre Fabre group:
The Pierre Fabre Group, the second largest independent French pharmaceutical company and leader in the field of in-pharmacy dermo-cosmetics, employs about 10,000 people worldwide, including 1,400 R&D staff, and generates a sales turnover of EUR1.8 billion.
In 2009, Pierre Fabre Medicament dedicated 28% of its annual turnover to R&D in four priority therapeutic areas in public health: oncology, central nervous system, dermatology, cardio-vascular/metabolism.
To learn more about Pierre Fabre, please refer to http://www.pierre-fabre.com.
ots Originaltext: Groupe Pierre Fabre
Im Internet recherchierbar: http://www.presseportal.ch
CONTACT: Press Contact : Djamila